A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

Completed · Phase 3

Conditions studied: Hypertriglyceridemia, Hyperlipoproteinemia Type IV

In brief

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.

Key facts

Study ID

NCT00134498

Run by

Pfizer

People needed

160

Starts

2005-02-01

Expected to finish

2006-11-01

Last updated by the study team

2007-11-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Fredrickson Type IV Hypertriglyceridemia

You may not qualify if…

• Women who are pregnant or lactating, or planning to become pregnant.
• Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
• Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
• Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study

Where it is running

• Pfizer Investigational Site — Anaheim, California, United States
• Pfizer Investigational Site — Huntington Beach, California, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Orange, California, United States
• Pfizer Investigational Site — Orangevale, California, United States
• Pfizer Investigational Site — Pacific Palisades, California, United States
• Pfizer Investigational Site — Studio City, California, United States
• Pfizer Investigational Site — Tustin, California, United States
• Pfizer Investigational Site — Walnut Creek, California, United States
• Pfizer Investigational Site — Farmington, Connecticut, United States
• Pfizer Investigational Site — Washington D.C., District of Columbia, United States
• Pfizer Investigational Site — Hollywood, Florida, United States
• Pfizer Investigational Site — Longwood, Florida, United States
• Pfizer Investigational Site — West Palm Beach, Florida, United States
• Pfizer Investigational Site — Tripler AMC, Hawaii, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Overland Park, Kansas, United States
• Pfizer Investigational Site — Baton Rouge, Louisiana, United States
• Pfizer Investigational Site — Scarborough, Maine, United States
• Pfizer Investigational Site — Bethesda, Maryland, United States
• Pfizer Investigational Site — Ann Arbor, Michigan, United States
• Pfizer Investigational Site — Canton, Michigan, United States
• Pfizer Investigational Site — Portage, Michigan, United States
• Pfizer Investigational Site — Richland, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.